Answers are grounded in this paper and cite their sources.
May support investigation of reperfusion injury; leaves open whether targeted therapies alter STEMI outcomes.
ST-segment elevation myocardial infarction (STEMI) is a consequence of atherosclerotic plaque rupture and thrombotic occlusion of the coronary artery causing downstream ischaemia and, eventually, cell death. The most effective therapeutic strategy for STEMI is timely reperfusion by primary percutaneous coronary intervention (PPCI). Such reperfusion is a prerequisite for myocardial salvage, leading to smaller infarct sizes and improved clinical outcomes [ 1 , 2 ]. However, reperfusion can itself inflict further injury, termed ischaemia-reperfusion injury (IRI). Despite PPCI, a recent study found 30-day, 1-year, and 5-year mortality following STEMI to be 7.9 %, 11.4 %, and 23.3 %, respectively [ 3 ]. Consequently, novel strategies to mitigate the deleterious effects of IRI are paramount.
No takes yet. Share an insight, caveat, or question.
Malik et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: